Jan 3 (Reuters) - Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
47.84 USD | +0.48% | +8.92% | +114.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+114.37% | 2.7B | |
+18.16% | 125B | |
+13.19% | 108B | |
-7.25% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.25% | 16.37B | |
+0.80% | 13.58B | |
+26.36% | 11.66B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios' blood disorder drug meets goals of late-stage study